Tempus AI Q3 revenue slightly beats estimates; raises guidance
TEM•Tempus AI reported third-quarter revenue of $411.54 million, up 23% and slightly above estimates, and adjusted EPS of $0.07. It raised its 2026 revenue guidance to $1.60 billion-$1.605 billion and maintained its adjusted EBITDA outlook at about $65 million.
1. Quarterly results
Third-quarter revenue was $411.54 million, compared with analysts’ $409.35 million estimate. Adjusted EPS was $0.07, versus an expected loss of $0.08 per share, while adjusted EBITDA was $25.57 million, above the $18.75 million estimate. The company reported a net loss of $14.85 million.
2. Guidance and drivers
Tempus AI raised its full-year 2026 revenue guidance to $1.60 billion-$1.605 billion and maintained its adjusted EBITDA outlook at about $65 million. The company said oncology test volumes grew 32%, diagnostics revenue was driven by that growth, and Data & Applications revenue rose 33%, with Insights up 29%. It also announced new collaborations with Merck, Moderna and BMS.
